ClinicalTrials.gg
CompletedNCT04221945Updated Nov 5, 2026Results posted

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

A Phase 3 interventional study of Pembrolizumab and Placebo for pembrolizumab in Uterine Cervical Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 176 sites in 30 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,060
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing pembrolizumab in Uterine Cervical Neoplasms — 11 open to participants now, 12 under way, 2 of them phase 3. pembrolizumab · Uterine Cervical Neoplasms.

Enrollment
2nd of 25
1,060 · median 94
Started
2020
with 4 others
Phase 3
4 of 25
1 open now
Registered
10th of 25
by date
Lead sponsor
4 of 25
Merck Sharp & Dohme LLC

Among the 25 studies testing pembrolizumab in Uterine Cervical Neoplasms, this one is the 2nd largest by enrollment, is one of 5 that started in 2020, is one of 4 in phase 3, and was the 10th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

11 of the 25 studies testing pembrolizumab in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing pembrolizumab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.

The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.

Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.

03

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • Programmed Cell Death Receptor 1 (PD-1, PD1)
  • Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1)
  • Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has high-risk locally advanced cervical cancer (LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage IB2-IIB (with node-positive disease) or FIGO 2014 Stages III-IVA
  • Has -confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
  • Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer, including agents, and is immunotherapy-naïve
  • Female participants must not be pregnant or breastfeeding and agree to use highly effective during the treatment period and for at least 120 days after the last dose of pembrolizumab or placebo and 180 days following the end of chemoradiotherapy and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period.
  • Female participants must abstain from breastfeeding during the study intervention period and for at least 120 days after the last dose of pembrolizumab or placebo and 180 days following the end of chemoradiotherapy
  • Has an (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment
  • Has provided a tissue sample from a core incisional or excisional of a tumor lesion
  • Has radiographically evaluable disease, either measurable or non-measurable per 1.1, as assessed by the local site investigator/radiology
  • Has adequate organ function within 7 days prior to the start of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Has excluded subtypes of LACC
  • Has FIGO 2014 Stage IVB disease
  • Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy
  • Has bilateral hydronephrosis, unless at least one side has been stented or resolved by positioning of nephrostomy or considered mild and not in the opinion of the investigator
  • Has anatomy or tumor geometry or any other reason or that cannot be treated with intracavitary brachytherapy or a combination of intracavitary and interstitial brachytherapy
  • Has received a within 30 days prior to the first dose of study treatment
  • Has received treatment with systemic immunostimulatory agents, colony stimulating factors, interferons, interleukins and vaccine combinations within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
  • Has received prior therapy with an anti-programmed cell death receptor 1 (), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)
  • Has received prior systemic anticancer therapy including agents within 4 weeks prior to randomization
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization
  • Has any contraindication to the use of cisplatin
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has severe to pembrolizumab and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of or known active virus infection
  • Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results, and in the judgment of the investigator or Sponsor, would make the participant inappropriate for entry into this study
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Has had an allogenic tissue/solid organ transplant
  • Has evidence of disease per 1.1 including lymph nodes above the first lumbar vertebra (L1) cephalad body, in the inguinal region
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,060 participants (actual)

Study arms

  • Experimental
    chemoradiotherapy + pembrolizumab

    Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).

    Biological: Pembrolizumab · Drug: Cisplatin · Radiation: External Beam Radiotherapy (EBRT) · Radiation: Brachytherapy

  • Experimental
    chemoradiotherapy + placebo for pembrolizumab

    Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).

    Drug: Placebo for pembrolizumab · Drug: Cisplatin · Radiation: External Beam Radiotherapy (EBRT) · Radiation: Brachytherapy

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: KEYTRUDA®, MK-3475

  • DrugPlacebo for pembrolizumab

    IV infusion

  • IV infusion

    Also known as: Platinol®, Platinol®-AQ

  • RadiationExternal Beam Radiotherapy (EBRT)

    Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed

  • RadiationBrachytherapy

    Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

    Time frame: Up to approximately 55 months

  2. Overall Survival (OS)

    OS is the time from randomization to death due to any cause. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate OS.

    Time frame: Up to approximately 55 months

Secondary outcomes

  1. PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

    Time frame: Up to approximately 55 months

  2. PFS Per RECIST 1.1 at Month 24 as Assessed by the Investigator

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The percentage of participants with PFS as assessed by the investigator is presented.

    Time frame: 24 months

  3. PFS Per RECIST 1.1 at Month 24 as Assessed by BICR

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The percentage of participants with PFS as assessed by BICR is presented.

    Time frame: 24 months

  4. Overall Survival (OS) at Month 36

    OS is the time from randomization to death due to any cause. The analysis was performed via Kaplan-Meier approach to estimate the OS rate at Month 36. The percentage of participants with OS at Month 36 is presented.

    Time frame: 36 months

  5. Complete Response (CR) Rate Per RECIST 1.1 at Week 12 as Assessed by the Investigator

    For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) per RECIST 1.1, CR rate is defined as the percentage of participants who experienced a CR. The percentage of participants with CR per RECIST 1.1 as assessed by the investigator at Week 12 is presented.

    Time frame: 12 weeks

  6. CR Rate Per RECIST 1.1 at Week 12 as Assessed by BICR

    For participants who demonstrated a confirmed CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) per RECIST 1.1, CR rate is defined as the percentage of participants who experienced a CR. The percentage of participants with CR per RECIST 1.1 as assessed by BICR at Week 12 is presented.

    Time frame: 12 weeks

  7. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by the Investigator

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions and includes no unequivocal progression in non-target lesions) per RECIST 1.1.

    Time frame: Up to approximately 55 months

  8. ORR Per RECIST 1.1 as Assessed by BICR

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions and includes no unequivocal progression in non-target lesions) per RECIST 1.1.

    Time frame: Up to approximately 55 months

  9. PFS Per RECIST 1.1 in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. PD-L1 positive participants have a combined positivity score (CPS) equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

    Time frame: Up to approximately 55 months

  10. PFS Per RECIST 1.1 in PD-L1 Positive Participants as Assessed by BICR

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. PD-L1 positive participants have a CPS equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

    Time frame: Up to approximately 55 months

  11. OS in PD-L1 Positive Participants

    OS is the time from randomization to death due to any cause. PD-L1 positive participants have a CPS equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate OS.

    Time frame: Up to approximately 55 months

  12. PFS After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment

    PFS is defined as the time from randomization to the first documented progressive disease (PD) on next-line treatment or death due to any cause, whichever occurs first, as assessed by the investigator. PFS 2 is measured after next-line treatment following discontinuation of study treatment administration.

    Time frame: Up to approximately 55 months

  13. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score

    The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The change from baseline in EORTC QLQ-C30 score will be presented.

    Time frame: Baseline and week 36

  14. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.

    Time frame: Baseline and week 36

  15. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score

    The EORTC QLQ-CX24 is a questionnaire that rates the symptoms common to women with cervical cancer and evaluates the impact of disease and/or treatments. The 24 items use a 4-point scale (1=not at all to 4=very much) and are classified into 3 multi-item scales, 11 items with symptom experience, 3 items with body image, and 4 items with sexual/ vaginal functioning. The other items of the questionnaire are lymphedema, peripheral neuropathy, menopausal symptom, sexual worry, sexual activity, and sexual enjoyment. Total scores are linearly transformed and range from 0 (no symptoms) to 100 (most severe symptoms). The change from baseline in EORTC QLQ-CX24 score is presented, with negative scores representing an improvement from baseline and vice versa.

    Time frame: Baseline and Week 36

  16. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to 55 months

  17. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to 32 months

07

Results

Posted Jan 5, 2026

Participant flow

The following participants were enrolled: had high-risk IB2-IIB (node-positive) or Stage III-IVA locally advanced cervical cancer (LACC); had histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix; had not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer, including investigational agents, and was immunotherapy-naïve; had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Participant flow — Overall Study
MilestoneChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Started529531
Treated528530
Completed00
Not completed529531
Withdrew: Death103140
Withdrew: Lost to follow-up58
Withdrew: Withdrawal by subject2111
Withdrew: Participants ongoing400372

Outcome measures

PrimaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator47.6 (47.6 to NA)47.5 (41.0 to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0004 (One sided p-value) · Hazard ratio (hr): 0.72 · 95% CI 0.59 to 0.87Based on Cox regression model with Efron's method of tie handling with treatment as a covariate
PrimaryOverall Survival (OS)

OS is the time from randomization to death due to any cause. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate OS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0076 (One sided p-value) · Hazard ratio (hr): 0.73 · 95% CI 0.57 to 0.94Based on Cox regression model with Efron's method of tie handling with treatment as a covariate
SecondaryPFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR)

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR)
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR)48.9 (48.9 to NA)NA (46.8 to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0011 (One-sided p-value) · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.89Based on Cox regression model with Efron's method of tie handling
SecondaryPFS Per RECIST 1.1 at Month 24 as Assessed by the Investigator

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The percentage of participants with PFS as assessed by the investigator is presented.

Time frame:
24 months
Reported as:
Number · Percentage of Participants
PFS Per RECIST 1.1 at Month 24 as Assessed by the Investigator
Percentage of ParticipantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS Per RECIST 1.1 at Month 24 as Assessed by the Investigator70.6 (66.4 to 74.3)59.7 (55.3 to 63.8)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Difference in survival rate: 10.9 · 95% CI 5.1 to 16.7Pembrolizumab minus Placebo
SecondaryPFS Per RECIST 1.1 at Month 24 as Assessed by BICR

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. The percentage of participants with PFS as assessed by BICR is presented.

Time frame:
24 months
Reported as:
Number · Percentage of Participants
PFS Per RECIST 1.1 at Month 24 as Assessed by BICR
Percentage of ParticipantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS Per RECIST 1.1 at Month 24 as Assessed by BICR76.0 (72.0 to 79.5)68.1 (63.8 to 72.0)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Difference in survival rate: 7.9 · 95% CI 2.3 to 13.5Pembrolizumab minus Placebo
SecondaryOverall Survival (OS) at Month 36

OS is the time from randomization to death due to any cause. The analysis was performed via Kaplan-Meier approach to estimate the OS rate at Month 36. The percentage of participants with OS at Month 36 is presented.

Time frame:
36 months
Reported as:
Number · Percentage of Participants
Overall Survival (OS) at Month 36
Percentage of ParticipantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Overall Survival (OS) at Month 3681.8 (78.1 to 84.9)74.4 (70.3 to 78.0)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Difference in survival rate: 7.4 · 95% CI 2.3 to 12.5Pembrolizumab minus Placebo
SecondaryComplete Response (CR) Rate Per RECIST 1.1 at Week 12 as Assessed by the Investigator

For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) per RECIST 1.1, CR rate is defined as the percentage of participants who experienced a CR. The percentage of participants with CR per RECIST 1.1 as assessed by the investigator at Week 12 is presented.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Complete Response (CR) Rate Per RECIST 1.1 at Week 12 as Assessed by the Investigator
Percentage of participantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Complete Response (CR) Rate Per RECIST 1.1 at Week 12 as Assessed by the Investigator36.9 (32.7 to 41.2)33.5 (29.5 to 37.8)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · One-sided p-value for testing · p = 0.1307 · Difference in percentage: 3.3 · 95% CI -2.5 to 9.1Pembrolizumab minus Placebo
SecondaryCR Rate Per RECIST 1.1 at Week 12 as Assessed by BICR

For participants who demonstrated a confirmed CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) per RECIST 1.1, CR rate is defined as the percentage of participants who experienced a CR. The percentage of participants with CR per RECIST 1.1 as assessed by BICR at Week 12 is presented.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
CR Rate Per RECIST 1.1 at Week 12 as Assessed by BICR
Percentage of participantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
CR Rate Per RECIST 1.1 at Week 12 as Assessed by BICR42.9 (38.6 to 47.2)42.2 (37.9 to 46.9)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · One-sided p-value for testing · p = 0.4082 · Difference in percentage: 0.7 · 95% CI -5.2 to 6.7Pembrolizumab minus Placebo
SecondaryObjective Response Rate (ORR) Per RECIST 1.1 as Assessed by the Investigator

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions and includes no unequivocal progression in non-target lesions) per RECIST 1.1.

Time frame:
Up to approximately 55 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by the Investigator
Percentage of participantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by the Investigator87.3 (84.2 to 90.1)83.7 (80.3 to 86.8)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · One-sided p-value for testing. · p = 0.0496 · Difference in percentage: 3.6 · 95% CI -0.7 to 7.9Pembrolizumab minus Placebo
SecondaryORR Per RECIST 1.1 as Assessed by BICR

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to \<10mm) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions and includes no unequivocal progression in non-target lesions) per RECIST 1.1.

Time frame:
Up to approximately 55 months
Reported as:
Number · Percentage of participants
ORR Per RECIST 1.1 as Assessed by BICR
Percentage of participantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
ORR Per RECIST 1.1 as Assessed by BICR90.5 (87.7 to 92.9)88.3 (85.3 to 90.9)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · One-sided p-value for testing. · p = 0.1244 · Difference in percentage: 2.2 · 95% CI -1.5 to 5.9Pembrolizumab minus Placebo
SecondaryPFS Per RECIST 1.1 in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. PD-L1 positive participants have a combined positivity score (CPS) equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
PFS Per RECIST 1.1 in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS Per RECIST 1.1 in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator47.6 (47.6 to NA)47.5 (41.0 to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0010 (One-sided p-value) · Hazard ratio (hr): 0.73 · 95% CI 0.59 to 0.89Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryPFS Per RECIST 1.1 in PD-L1 Positive Participants as Assessed by BICR

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD. PD-L1 positive participants have a CPS equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate PFS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
PFS Per RECIST 1.1 in PD-L1 Positive Participants as Assessed by BICR
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS Per RECIST 1.1 in PD-L1 Positive Participants as Assessed by BICR48.9 (48.9 to NA)NA (46.8 to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0016 (One-sided p-value) · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.90Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryOS in PD-L1 Positive Participants

OS is the time from randomization to death due to any cause. PD-L1 positive participants have a CPS equal or greater than 1. The Kaplan-Meier nonparametric product limit method for censored data was used to estimate OS.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
OS in PD-L1 Positive Participants
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
OS in PD-L1 Positive ParticipantsNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0083 (One-sided p-value) · Hazard ratio (hr): 0.73 · 95% CI 0.56 to 0.95Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryPFS After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment

PFS is defined as the time from randomization to the first documented progressive disease (PD) on next-line treatment or death due to any cause, whichever occurs first, as assessed by the investigator. PFS 2 is measured after next-line treatment following discontinuation of study treatment administration.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
PFS After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment
MonthsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
PFS After Next-Line Treatment (PFS 2) Following Discontinuation of Study TreatmentNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · Log Rank · p = 0.0015 (One-sided p-value) · Hazard ratio (hr): 0.69 · 95% CI 0.54 to 0.88Based on Cox regression model with Efron's method of tie handling with treatment as a covariate
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score

The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The change from baseline in EORTC QLQ-C30 score will be presented.

Time frame:
Baseline and week 36
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score
Score on a scaleChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score7.51 (5.30 to 9.73)7.44 (5.23 to 9.66)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · cLDA model · p = 0.9593 · Difference ls means: 0.07 · 95% CI -2.66 to 2.80Pembrolizumab minus placebo
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.

Time frame:
Baseline and week 36
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score
Score on a scaleChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score2.74 (1.16 to 4.33)2.07 (0.48 to 3.65)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · cLDA model · p = 0.5145 · Difference ls means: 0.68 · 95% CI -1.36 to 2.71Pembrolizumab minus placebo
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score

The EORTC QLQ-CX24 is a questionnaire that rates the symptoms common to women with cervical cancer and evaluates the impact of disease and/or treatments. The 24 items use a 4-point scale (1=not at all to 4=very much) and are classified into 3 multi-item scales, 11 items with symptom experience, 3 items with body image, and 4 items with sexual/ vaginal functioning. The other items of the questionnaire are lymphedema, peripheral neuropathy, menopausal symptom, sexual worry, sexual activity, and sexual enjoyment. Total scores are linearly transformed and range from 0 (no symptoms) to 100 (most severe symptoms). The change from baseline in EORTC QLQ-CX24 score is presented, with negative scores representing an improvement from baseline and vice versa.

Time frame:
Baseline and Week 36
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score
Score on a scaleChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score-8.86 (-10.03 to -7.69)-9.60 (-10.78 to -8.43)
Statistical analysis
  • Chemoradiotherapy + Pembrolizumab vs Chemoradiotherapy + Placebo for Pembrolizumab · cLDA model · p = 0.2953 · Difference ls means: 0.75 · 95% CI -0.65 to 2.15Pembrolizumab minus placebo
SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

Time frame:
Up to 55 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
ParticipantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Number of Participants Who Experience One or More Adverse Events (AEs)528526
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an AE
ParticipantsChemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for Pembrolizumab
Number of Participants Who Discontinue Study Treatment Due to an AE11279

Adverse events

Collected over All-cause mortality (ACM): from allocation up to a maximum of 55 months. Adverse events (AEs): from start of treatment up to a maximum of 55 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + CCRT107/529 (20.2%)175/528 (33.1%)528/528 (100%)
Placebo + CCRT140/531 (26.4%)153/530 (28.9%)525/530 (99.1%)
Most frequent serious events
Showing 10 of 237
Most frequent serious events
EventPembrolizumab + CCRTPlacebo + CCRT
Urinary tract infectionInfections and infestations18/52813/530
AnaemiaBlood and lymphatic system disorders16/52813/530
PyrexiaGeneral disorders14/52810/530
DiarrhoeaGastrointestinal disorders10/5286/530
PyelonephritisInfections and infestations6/5286/530
SepsisInfections and infestations6/5285/530
HydronephrosisRenal and urinary disorders6/5283/530
Vaginal haemorrhageReproductive system and breast disorders6/5285/530
Acute kidney injuryRenal and urinary disorders4/5286/530
Febrile neutropeniaBlood and lymphatic system disorders5/5284/530
Most frequent other events
Showing 10 of 59
Most frequent other events
EventPembrolizumab + CCRTPlacebo + CCRT
AnaemiaBlood and lymphatic system disorders356/528342/530
NauseaGastrointestinal disorders318/528337/530
DiarrhoeaGastrointestinal disorders297/528296/530
White blood cell count decreasedInvestigations175/528187/530
VomitingGastrointestinal disorders158/528177/530
Neutrophil count decreasedInvestigations164/528151/530
Urinary tract infectionInfections and infestations113/528145/530
LeukopeniaBlood and lymphatic system disorders129/52897/530
HypomagnesaemiaMetabolism and nutrition disorders129/528124/530
NeutropeniaBlood and lymphatic system disorders124/528107/530

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Chemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for PembrolizumabTotal
Mean49.4 ± 11.950.1 ± 12.349.8 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Chemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for PembrolizumabTotal
Female5295311060
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Chemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for PembrolizumabTotal
Hispanic or Latino161173334
Not Hispanic or Latino363356719
Unknown or Not Reported527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Chemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for PembrolizumabTotal
American Indian or Alaska Native242246
Asian156148304
Native Hawaiian or Other Pacific Islander213
Black or African American14822
White254264518
More than one race7886164
Unknown or Not Reported123
PDL-1 Status
PDL-1 Status(Participants)Chemoradiotherapy + PembrolizumabChemoradiotherapy + Placebo for PembrolizumabTotal
CPS<1222850
CPS>=15024981000
Missing5510
08

Study locations

176 sites
  • HonorHealth Research Institute - Biltmore ( Site 8009)
    Phoenix, Arizona 85016, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027)
    Los Angeles, California 90095, United States
  • Hoag Memorial Hospital Presbyterian ( Site 0038)
    Newport Beach, California 92663, United States
  • UC Davis Comprehensive Cancer Center ( Site 0017)
    Sacramento, California 95817, United States
  • University of Colorado Health Sciences Center and Hospital ( Site 0028)
    Denver, Colorado 80262, United States
  • Smilow Cancer Center at Yale-New Haven ( Site 0023)
    New Haven, Connecticut 06510, United States
  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 0009)
    Orlando, Florida 32804, United States
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0026)
    Fort Wayne, Indiana 46845, United States
  • University of Kentucky Markey Cancer Center ( Site 0015)
    Lexington, Kentucky 40536, United States
  • Our Lady of the Lake Regional Medical Center. ( Site 0031)
    Baton Rouge, Louisiana 70817, United States
  • Women's Cancer Care ( Site 0039)
    Covington, Louisiana 70433, United States
  • Karmanos Cancer Institute ( Site 0018)
    Detroit, Michigan 48201, United States
  • Minnesota Oncology Hematology, PA ( Site 8007)
    Minneapolis, Minnesota 55404, United States
  • University of New Mexico Comprehensive Cancer Center-Clinical Research Office ( Site 0019)
    Albuquerque, New Mexico 87106, United States
  • University of North Carolina at Chapel Hill ( Site 0025)
    Chapel Hill, North Carolina 27514, United States
  • Sanford Bismarck Medical Center ( Site 0046)
    Bismarck, North Dakota 58501, United States
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
    Columbus, Ohio 43210, United States
  • Willamette Valley Cancer Institute and Research Center ( Site 8000)
    Eugene, Oregon 97401, United States
  • Legacy Good Samaritan Medical Center ( Site 0013)
    Portland, Oregon 97210, United States
  • Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030)
    Pittsburgh, Pennsylvania 15244, United States
  • Hollings Cancer Center ( Site 0007)
    Charleston, South Carolina 29425, United States
  • Sanford Gynecology Oncology ( Site 0003)
    Sioux Falls, South Dakota 57104, United States
  • Texas Oncology-Austin Central ( Site 8006)
    Austin, Texas 78731, United States
  • Texas Oncology-Fort Worth Cancer Center ( Site 8001)
    Fort Worth, Texas 76104, United States
  • Texas Oncology-San Antonio Medical Center ( Site 8002)
    San Antonio, Texas 78240, United States
  • Texas Oncology-The Woodlands ( Site 8003)
    The Woodlands, Texas 77380, United States
  • UVA Health System ( Site 0005)
    Charlottesville, Virginia 22908, United States
  • Virginia Commonwealth University ( Site 0024)
    Richmond, Virginia 23219, United States
  • Westmead Hospital ( Site 0973)
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women s Hospital ( Site 0972)
    Herston, Queensland 4029, Australia
  • Monash Health-Monash Medical Centre ( Site 0970)
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre ( Site 0971)
    Melbourne, Victoria 3000, Australia
  • St John of God Subiaco Hospital ( Site 0969)
    Subiaco, Western Australia 6008, Australia
  • Medizinische Universität Wien ( Site 0567)
    Vienna, State of Vienna 1090, Austria
  • Medizinische Universitat Graz ( Site 0569)
    Graz, Styria 8036, Austria
  • Medizinische Universitat Innsbruck ( Site 0566)
    Innsbruck, Tyrol 6020, Austria
  • UZA University Hospital Antwerp ( Site 0351)
    Edegem, Antwerpen 2650, Belgium
  • GZA Sint Augustinus ( Site 0356)
    Wilrijk, Antwerpen 2610, Belgium
  • C.I.U. Hopital Ambroise Pare ( Site 0353)
    Mons, Hainaut 7000, Belgium
  • OLV Ziekenhuis ( Site 0352)
    Aalst, Oost-Vlaanderen 9300, Belgium
  • AZ St Lucas ( Site 0349)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 0354)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Hospital das Clinicas da UFMG ( Site 0172)
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Liga Norte Riograndense Contra o Cancer ( Site 0170)
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Hospital de Clínicas de Ribeirão Preto ( Site 0171)
    Ribeirão Preto, São Paulo 14048900, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0166)
    São Paulo, São Paulo 04014-002, Brazil
  • Instituto Nacional Do Cancer II ( Site 0173)
    Rio de Janeiro, 20220-410, Brazil
  • Princess Margaret Cancer Centre ( Site 0102)
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0101)
    Montreal, Quebec H2X 0A9, Canada
  • McGill University Health Centre ( Site 0105)
    Montreal, Quebec H4A 3J1, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
    Québec, Quebec G1J 1Z4, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0194)
    Temuco, Araucania 4800827, Chile
  • Sociedad Oncovida S.A. ( Site 0196)
    Santiago, Region M. de Santiago 7510032, Chile
  • Iram Cancer Research ( Site 0198)
    Santiago, Region M. de Santiago 7630370, Chile
  • Oncocentro ( Site 0195)
    Viña del Mar, Valparaiso, Chile
  • Anhui Provincial Hospital ( Site 1029)
    Hefei, Anhui 230001, China
  • Anhui Provincial Cancer Hospital ( Site 1007)
    Hefei, Anhui 230031, China
  • Peking Union Medical College Hospital ( Site 1001)
    Beijing, Beijing Municipality 100730, China
  • Chongqing Cancer Hospital ( Site 1030)
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated Hospital of Xiamen University ( Site 1025)
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital.Sun Yat-sen University ( Site 1005)
    Guangzhou, Guangdong 510080, China
  • Affiliated Cancer Hospital of Guangxi Medical University ( Site 1036)
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital ( Site 1013)
    Harbin, Heilongjiang 150081, China
  • Hunan Cancer Hospital ( Site 1015)
    Changsha, Hunan 233004, China
  • Xiangya Hospital Central-South University ( Site 1009)
    Changsha, Hunan 410008, China
  • Shanghai Cancer Hospital ( Site 1000)
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 1039)
    Shanghai, Shanghai Municipality 201204, China
  • Sichuan Cancer Hospital ( Site 1018)
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital of Xinjiang Medical University ( Site 1012)
    Ürümqi, Xinjiang 830054, China
  • Zhejiang Provincial People's Hospital ( Site 1021)
    Hangzhou, Zhejiang 310014, China
  • Zhejiang Cancer Hospital ( Site 1004)
    Hangzhou, Zhejiang 310022, China
  • Fundacion Centro de Investigacion Clinica CIC ( Site 0231)
    Medellín, Antioquia 050021, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 0228)
    Bogotá, Bogota D.C. 110321, Colombia
  • Fundacion Valle del Lili ( Site 0230)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0227)
    Cali, Valle del Cauca Department 760042, Colombia
  • Fakultni Nemocnice Brno Bohunice ( Site 0912)
    Brno, Brno-mesto 602 00, Czechia
  • Fakultni nemocnice Ostrava ( Site 0909)
    Ostrava, Moravian-Silesian Region 708 52, Czechia
  • Fakultni nemocnice Kralovske Vinohrady ( Site 0913)
    Prague, 100 34, Czechia
  • CHU Jean Minjoz ( Site 0411)
    Besançon, Doubs 25000, France
  • Institut Claudius Regaud ( Site 0417)
    Toulouse, Haute-Garonne 31059, France
  • Centre Hospitalier Lyon Sud ( Site 0413)
    Pierre-Bénite, Rhone 69310, France
  • Universitaetsklinikum Freiburg ( Site 0454)
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitätsmedizin Mannheim-Department of Obstetrics and Gynecology ( Site 0443)
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Klinikum der Universitaet in Muenchen ( Site 0446)
    Munich, Bavaria 80336, Germany
  • Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0453)
    Munich, Bavaria 81675, Germany
  • Universitaetsklinikum Carl Gustav Carus der Technischen Univ ( Site 0452)
    Dresden, Saxony 01307, Germany
  • Universitaetsklinik Leipzig ( Site 0456)
    Leipzig, Saxony 04103, Germany
  • Charite Universitaetsmedizin Berlin ( Site 0442)
    Berlin, 13353, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0445)
    Hamburg, 20246, Germany
  • General Hospital of Patras. St Andrews ( Site 0473)
    Pátrai, Achaia 262 00, Greece
  • Alexandra General Hospital ( Site 0477)
    Athens, Attica 11528, Greece
  • Hospital Hygeia ( Site 0478)
    Athens, Attica 151 23, Greece
  • Euromedica General Clinic of Thessaloniki ( Site 0474)
    Thessaloniki, 546 45, Greece
  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0321)
    Guatemala City, 01010, Guatemala
  • Oncologika S.A. ( Site 0323)
    Guatemala City, 01010, Guatemala
  • Oncomedica ( Site 0320)
    Guatemala City, 01010, Guatemala
  • Grupo Angeles SA ( Site 0319)
    Guatemala City, 01015, Guatemala
  • Medi-K Cayala ( Site 0318)
    Guatemala City, 01016, Guatemala
  • Centro Medico Integral De Cancerología (CEMIC) ( Site 0322)
    Quetzaltenango, 09002, Guatemala
  • Orszagos Onkologiai Intezet ( Site 0846)
    Budapest, 1122, Hungary

Showing the first 100 of 176 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejia F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampe R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. PubMed 38521086 ↗
  • Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejia F, Helpman L, Akilli H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Oct 5;404(10460):1321-1332. doi: 10.1016/S0140-6736(24)01808-7. Epub 2024 Sep 14. PubMed 39288779 ↗
  • Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V, Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025 Aug;199:88-95. doi: 10.1016/j.ygyno.2025.06.003. Epub 2025 Jun 30. PubMed 40592026 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jan 2025, 55 months.

Results were first posted in Jan 2026, 11 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 55 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Jan 9, 2020
StartActual
May 12, 2020
Primary completionActual
Jan 7, 2025
CompletionActual
Jan 26, 2026
Results first posted
Jan 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, site details and references
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04221945
Collaborators
GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Jan 9, 2020
Start date
May 12, 2020
Primary completion
Jan 7, 2025
Completion
Jan 26, 2026
Results posted
Jan 5, 2026
Last update
Nov 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion